BioAge Labs: Developing A 'Pipeline In A Pill'
Source: SeekingAlpha
2026-06-24 17:11:34 ET
Today, I am putting BioAge Labs ( BIOA ) in the spotlight for the first time on these pages. Consistent revenue growth is projected to be years away, but the company has a huge cash hoard that will fund all operations for many years as management executes against its developmental plans. The shares have moved up sharply in recent months and are back near where the company came public in 2023. Should investors continue to bet for brighter days ahead? A first analysis follows below....
Read the full article on Seeking Alpha
For further details see:
BioAge Labs: Developing A 'Pipeline In A Pill'
BioAge Labs Inc.
NASDAQ: BIOA
BIOA Trading
-10.03% G/L:
$21.80 Last:
419,343 Volume:
$23.82 Open:
BIOA Latest News
June 16, 2026 08:00:00 am
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
May 20, 2026 09:50:00 am
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
$842,881,460
21,825,578
0.4%
24
N/A
Pharmaceuticals
Healthcare
US
Emeryville
